Clobazam
- 30 October 2012
- journal article
- review article
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 28 (2), 219-229
- https://doi.org/10.1177/0883073812463609
Abstract
Clobazam, a 1,5-benzodiazepine, was introduced in the 1970s as an anxiolytic and antiepileptic drug. Despite worldwide usage, it was only recently approved in the United States (seizures associated with Lennox-Gastaut syndrome). This article reviews historical and recent data to help practitioners better understand clobazam’s clinical properties and usage. In many clinical trials, open-label studies, and retrospective reviews, clobazam was generally associated with ≥50% seizure reduction for more than half of Lennox-Gastaut syndrome patients, with approximately 10% achieving freedom from drop attacks. Efficacy is persistent, with little evidence for development of tolerance. Clobazam’s safety profile appears to be similar to that of other benzodiazepines, but with substantially decreased sedation and increased psychomotor performance. Studies suggest clobazam acts through potentiation of gamma-aminobutyric acid type A receptors in a manner similar to other benzodiazepines. However, clobazam appears to display greater selectivity for receptors responsible for anticonvulsant activity than for those involved in sedation.Keywords
This publication has 48 references indexed in Scilit:
- GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine ClobazamCNS Drugs, 2012
- From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resourceBiomarkers in Medicine, 2011
- Randomized, phase III study results of clobazam in Lennox-Gastaut syndromeNeurology, 2011
- Interactions between modulators of the GABAA receptor: Stiripentol and benzodiazepinesEuropean Journal of Pharmacology, 2011
- Clobazam in the treatment of Lennox‐Gastaut syndromeEpilepsia, 2009
- IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISMDrug Metabolism and Disposition, 2006
- A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazamBrain & Development, 2004
- Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With EpilepsyTherapeutic Drug Monitoring, 1999
- Geographical/Interracial Differences in Polymorphic Drug OxidationClinical Pharmacokinetics, 1995
- Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsyBrain & Development, 1991